• Disease Overview
  • Synonyms
  • Signs & Symptoms
  • Causes
  • Affected Populations
  • Disorders with Similar Symptoms
  • Diagnosis
  • Standard Therapies
  • Clinical Trials and Studies
  • Resources
  • References
  • Programs & Resources
  • Complete Report

Fibromuscular Dysplasia

Print

Last updated: February 01, 2017
Years published: 2006, 2011, 2014, 2017


Acknowledgment

NORD gratefully acknowledges Pamela Mace, RN, Executive Director of the Fibromuscular Dysplasia Society of America and Heather Gornik, MD, Medical Director, Noninvasive Vascular Laboratory, Cleveland Clinic Heart and Vascular Institute, for assistance in the preparation of this report.


Disease Overview

Fibromuscular dysplasia, commonly called FMD, is a disease that causes one or more arteries in the body to have abnormal cell development in the artery wall. As a result, areas of narrowing (stenosis), aneurysms, or tears (dissection) may occur. If narrowing or a tear causes a decrease in blood flow through the artery, symptoms may result. FMD is most commonly found in the arteries that supply the kidneys with blood (renal arteries) and the arteries called the carotid and vertebral arteries which are found in the neck and supply the brain with blood. Less commonly, FMD affects the arteries in the abdomen (supplying the liver, spleen and intestines) and extremities (legs and arms). In more than one-half of people with this disease, there will be evidence of FMD in more than one artery.

Recently, studies have shown that some women who were healthy and who have a sudden tearing of a coronary artery (called sudden coronary artery dissection or “SCAD”) probably have undiagnosed FMD. SCAD was previously thought to be a separate condition to FMD, but now we are starting to understand that many people have FMD as the main reason for their coronary tear.

  • Next section >
  • < Previous section
  • Next section >

Synonyms

  • FMD
  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Signs & Symptoms

Some people with this disease do not have symptoms or findings on a physical examination. The signs and/or symptoms that a person with FMD may experience depend on the arteries affected and whether there is narrowing, tears, or aneurysms within them. Any pain or clinical sign related to FMD typically comes from the organ that is supplied by that artery. For example, FMD in the kidney arteries may cause high blood pressure. FMD in the carotid arteries may cause headaches or a swooshing sound in the ears (called pulsatile tinnitus). Some patients with FMD may have no symptoms at all but are diagnosed with this disease when a physician hears a noise over one of the arteries due to disturbed or turbulent blood flow within the vessel. This noise is known as a bruit.

A person with severe carotid FMD causing severe narrowing or a tear in a carotid or vertebral artery may have neurologic symptoms involving the facial nerves (drooping of the eye lid, unequal size of the pupils, for example), stroke or transient ischemic attack. People with carotid FMD have a higher risk for aneurysms of the arteries in the brain (intracranial aneurysms). Bleeding in the brain (intracranial hemorrhage) may occur if an aneurysm ruptures, and it is important to identify and treat brain aneurysms early to prevent this.

FMD involving the arteries that supply the intestines, liver and spleen with blood (mesenteric arteries) can result in abdominal pain after eating and unintended weight loss. FMD in the arms and legs can cause limb discomfort with exercise or can lead to unequal blood pressures in the arms.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Causes

The cause of FMD is not yet known, but several theories have been suggested. A number of case reports in the literature have identified the disease in multiple members of the same family including twins. As a result, it is felt that there may be a genetic cause. However, a relative may have different artery involvement, different disease severity, or not develop FMD at all. In fact, most individuals with FMD do not have a family member who also has the disease. Among some individuals with FMD, there is a family history of other vascular problems, such as blood vessel aneurysms.

FMD is far more commonly seen in women than in men, resulting in the theory that hormones may play an important role in disease development. However, in small population studies, one’s reproductive history (number of pregnancies and when they occurred) as well as use of birth control pills did not correlate with the development of FMD.

Other possible causes of FMD include abnormal development of the arteries that supply the vessel wall with blood, resulting in inadequate oxygen supply; the anatomic position or movement of the artery within the body; certain medications, and tobacco use. It is possible that many factors contribute to the development of FMD. This area requires further research.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Affected populations

FMD affects women far more commonly than men, although men and children can be affected with this disease. In children with FMD, the disease seems to more commonly present with significant narrowing rather than tears of arteries and also seems to involve the arteries to the kidneys and intestines more commonly than the carotid vessels. In the pediatric population, FMD affects both boys and girls.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Diagnosis

In order to diagnosis FMD, a test must be done to image the blood vessels. There are many options for imaging the arteries, including specialized blood vessel ultrasound known as duplex ultrasound; a CAT scan of the arteries which is obtained after a dye is given through the veins, or a special type of MRI. In many cases, the diagnosis of FMD requires that a procedure known as an arteriogram be performed. Arteriography is a procedure that is performed by a radiologist, vascular surgeon, cardiologist, or vascular medicine specialist with appropriate training. It involves inserting a wire into or near the affected artery and injecting contrast material, a dye that can be detected by an X-ray machine. An X-ray of the affected area is then taken and examined. The individual is usually awake during an arteriogram procedure although medications may be given to keep her or him comfortable. This outpatient procedure usually lasts from one to two hours with a recovery period of up to six hours (this varies widely).

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Standard Therapies

Treatment
There is no cure for FMD. Treatments are focused on managing symptoms and complications of FMD, including high blood pressure and headaches. Antiplatelet medications, such as aspirin, may be prescribed along with medications to treat high blood pressure (anti hypertensives). Many patients with FMD suffer from headaches, and a number of medications are available to help control and prevent headaches. All patients with FMD who use tobacco should be encouraged to quit.

In some cases of FMD, an attempt should be made to improve the flow of blood through a severely narrowed vessel. The kind of treatment used for narrowing due to FMD depends largely upon which arteries are affected and the presence and severity of the symptoms. In most cases, such procedures are done using balloon angioplasty, a procedure known as percutaneous transluminal angioplasty (PTA). PTA is often performed at the same time as an arteriogram.

If an angioplasty is performed, a catheter is extended into the affected artery and a small balloon is inflated in the artery. A metal stent is typically not required to keep the vessel open, but may be needed in some cases, such as for treatment of a tear (dissection) of a blood vessel. If angioplasty is performed, the procedure and recovery period may be longer than an arteriogram done for diagnosis only. Occasionally, traditional open surgery is performed to treat severe narrowing due to FMD, particularly those that cannot be treated with angioplasty.

Patients with FMD who are found to have a significant aneurysm within the brain or renal arteries may need to undergo surgery even without symptoms. In such cases, it is recommended that the aneurysm be treated to prevent rupture which can be potentially life threatening. The type of treatment for an arterial aneurysm depends on its location and size. Treatment options for aneurysms include traditional open surgery or a less invasive angiogram-based procedure which treats the aneurysm using special vascular coils and/or stents.

The appropriate treatment will vary with each individual and severity, location, and extent of disease. The treatment plan should be discussed in depth with a specialist who is very knowledgeable about FMD and its natural history.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Clinical Trials and Studies

The FMD Society of America is sponsoring the United States patient registry for FMD, which is gathering information regarding the epidemiology, symptoms, disease extent, treatments, and outcomes of patients who have FMD. To learn more about the FMD patient registry, go to https://www.fmdsa.org/research_network/fmd_registry

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov . All studies receiving U.S. government funding, and some supported by private industry, are posted on this government website.

For information about clinical trials being conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Toll free: (800) 411-1222
TTY: (866) 411-1010
Email: prpl@cc.nih.gov

For information about clinical trials sponsored by private sources, contact: www.centerwatch.com

For information about clinical trials conducted in Europe, contact: https://www.clinicaltrialsregister.eu/

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Resources

RareConnect offers a safe patient-hosted online community for patients and caregivers affected by this rare disease.  For more information, visit www.rareconnect.org.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

References

TEXTBOOKS
Kasper, DL, Fauci AS, Longo DL, et al., eds. Harrison’s Principles of Internal Medicine.

16th ed. McGraw-Hill Companies. New York, NY; 2005:1469-71, 1707-08, 2378.

Badr KF, Brenner BM. Vascular injury to the kidney. In: Brenner BM, Rector Jr FC. The Kidney. 4th ed. W.B. Saunders Company. Philadelphia, PA; 1991:1948-49.

JOURNAL ARTICLES
Green R, Gu X, Kline-Rogers E, Froehlich J, Mace P, Gray B, Katzen B, Olin J, Gornik HL, Cahill AM, Meyers KE. Differences between the pediatric and adult presentation of fibromuscular dysplasia: results from the US registry. Pediatric Nephrology. 2015; 1-10. DOI:10.1007/s00467-015-3234-z. https://www.ncbi.nlm.nih.gov/pubmed/26525198

Weinberg I, Gu X, Giri J, Kim SE, Bacharach MJ, Gray BH, Katzen BT, Matsumoto AH, Chi YW, Rogers KR, Froehlich J, Olin JW, Gornik HL, Jaff MR. Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia: results from the United States registry for fibromuscular dysplasia. Vasc Med. 2015;20(5):447-453. https://vmj.sagepub.com/content/20/5/447.full.pdf+html

Sharma AM, Kline B. The United States registry for fibromuscular dysplasia: new findings and breaking myths. Tech Vasc Interventional Rad. 2014;17(4):258-263. https://dx.doi.org/10.1053/j.tvir.2014.11.007

Kim ESH, Olin JW, Froehlich JB, Gu X, Bacharach JM, Gray BH, Jaff MR, Katzen BT, Kline-Rogers E, Mace P, Matsumoto AH, McBane RD, White CJ, Gornik HL. Clinical manifestations of fibromuscular dysplasia vary by patient sex: a report of the United States registry for fibromuscular dysplasia. JACC. 2013;62(21):2026-2028.

Olin JW, Froehlich J, Gu X, Bacharach M, Eagle K, Gray B, Jaff MR, Kim E, Mace P, Matsumoto AH, McBane R, Kline-Rogers E, White C, Gornik HL. The United States registry for fibromuscular dysplasia: results in the first 447 patients. Circulation 2012;125(25):3182-3190. https://circ.ahajournals.org/content/circulationaha/early/2012/05/21/CIRCULATIONAHA.112.091223.full.pdf

Poloskey SL, Olin JW, Mace P, Gornik HL. Fibromuscular dysplasia patient page. Circulation. 2012;125:e636-e639. https://circ.ahajournals.org/content/circulationaha/125/18/e636.full.pdf

INTERNET
Chen M. Renovascular hypertension. MedlinePlus. Updated 5/5/2016. Available at https://medlineplus.gov/ency/article/000204.htm Accessed January 30, 2017.

McKusick VA, ed. Online Mendelian Inheritance In Man (OMIM). The Johns Hopkins University. Fibromuscular Dysplasia of Arteries. Entry Number 135580. Available at https://omim.org/entry/135580 Last Edit Date 09/10/2013. Accessed January 30, 2017.

  • < Previous section
  • Next section >

Programs & Resources

RareCare® Assistance Programs

NORD strives to open new assistance programs as funding allows. If we don’t have a program for you now, please continue to check back with us.

Additional Assistance Programs

MedicAlert Assistance Program

NORD and MedicAlert Foundation have teamed up on a new program to provide protection to rare disease patients in emergency situations.

Learn more https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/

Rare Disease Educational Support Program

Ensuring that patients and caregivers are armed with the tools they need to live their best lives while managing their rare condition is a vital part of NORD’s mission.

Learn more https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/

Rare Caregiver Respite Program

This first-of-its-kind assistance program is designed for caregivers of a child or adult diagnosed with a rare disorder.

Learn more https://rarediseases.org/patient-assistance-programs/caregiver-respite/

Patient Organizations


National Organization for Rare Disorders